IMM01, developed internally by ImmuneOnco, is a novel proprietary immunotherapeutic molecule. IMM01 works by inhibiting CD47 and potently promoting antibody-dependent cellular phagocytosis (ADCP); it activates macrophages to engulf tumor cells and present tumor antigens to T cells, thus directing potent immune responses against tumor cells. Further, IMM01 does not bind human red blood cells, which is a common side effect of other anti-CD47 compounds.
IMM2902, a novel proprietary bispecific targeting CD47 and HER2, was designed based on ImmuneOnco’s “mAb- Trap” platform technology. The HER2 antibody portion of IMM2902 inhibits tumor growth by accelerating HER2 endocytosis and degradation; while the “Trap” (modified SIRPa) portion if IMM2902 inhibits “don’t eat me” signal and activates “eat me” signal from tumor cells, activates macrophages to engulf tumor cells and present tumor antigens to T cells, thus directing potent immune responses against tumor cells. Main indications of IMM2902 include HER2 positive breast cancer, stomach cancer, lung cancer and other solid tumors.
IMM0306 is our proprietary mAb-Trap fusion protein that simultaneously targets CD47 and CD20 and a potentially First-in-Class therapeutic compound. It targets both tumor marker CD20 and SIRPa-CD47 immune pathway, by activating macrophages and natural killer cells for potent antitumor effects.
IMM2510 is a bi-specific antibody with intellectual property rights, developed based on the unique "mAb-Trap" technical platform of ImmuneOnco. IMM2510 eliminates the immune escape of tumor cells via blocking PD-L1/ PD-1 signaling pathway by targeting PD-L1, and it also activates NK cells and macrophages via Fc-mediated ADCC/ADCP which plays a powerful effect in tumor immunotherapy. At the same time, tumor growth and metastasis were greatly inhibited by blocking VEGF/VEGFR signaling pathway which promotes tumor angiogenesis. Preclinical studies confirmed that IMM2510 achieved significant therapeutic effects in a variety of tumor models. The anti-tumor effect of IMM2510 is superior to the single drug or the combination of two targets with significant advantages of safety. The IMM2510 is designed to use in a variety of indications of advanced solid tumors.
IMM27M is a new generation of CTLA-4 antibody developed by ImmueOnco. By genetic engineering modification, the ADCC activity has been greatly enhanced so as to eliminate Treg cells completely from tumor microenvironment. IMM27M is, not only efficacious in mono drug therapy, but also could be administrated in combination with a variety of drug candidates in the product pipeline such as IMM01 (CD47), IMM2510 (VEGF/PD-L1), IMM2902 (CD47/Her2), IMM2520 (CD47/PD-L1).